{"entity":{"id":"selectmdx","kind":"drug","name":"SelectMDx","aka":["Select mdx","SelectMDx for Prostate Cancer"],"tldr":"A urine test taken after a prostate examination that reads two genes to estimate the chance of a high-grade cancer; its maker is moving customers to its newer urine test.","summary":"Medicare's code 0339U describes \"MRNA EXPRESSION PROFILING OF HOXC6 AND DLX1\" in \"FIRST-VOID URINE FOLLOWING DIGITAL RECTAL EXAMINATION\", and Palmetto MolDX article A58700 lists it for the pre-biopsy setting. In its validation the combined clinical and urine model reached an area under the curve of 0.90 (95% CI 0.85 to 0.95) for high-grade cancer (Van Neste 2016). MDxHealth's third-quarter 2025 results describe \"transitioning our Select mdx customers to ExoDx\"; no statement of withdrawal was found.","status":"established","asOf":"2026-11-04","links":[{"label":"MDxHealth: third-quarter 2025 results","url":"https://mdxhealth.com/press_release/mdxhealth-reports-results-for-the-third-quarter-and-nine-month-period-ended-september-30-2025-2/"},{"label":"CMS article A58700: Billing and Coding: MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer","url":"https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=58700"}],"tags":["test","rna"],"related":["exodx-prostate","myprostatescore-2"],"cancers":["prostate"],"sections":[],"technologies":["liquid-rna-biopsy","prostate-screening-psa-mri"],"targets":[],"drugs":[],"companies":["mdxhealth"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-van-neste-urinary-biomarker-prostate-eur-urol-2016"],"journals":[],"dependsOn":[],"notes":[],"brand":"Select mdx","modality":"Urine mRNA test (HOXC6 and DLX1, prostate biopsy decision)","mechanism":"mRNA of HOXC6 and DLX1 relative to KLK3 is measured in first-void urine collected after a digital rectal examination and combined with clinical factors.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[{"country":"US","reimbursement":"Medicare (Palmetto MolDX billing article A58700) lists SelectMDx for men at increased risk of prostate cancer before biopsy","source":"https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=58700","asOf":"2026-11-04"}],"regulatoryEvents":[]},"route":"/drugs/selectmdx/","neighbours":{"drug":[{"id":"exodx-prostate","kind":"drug","name":"ExoDx Prostate (IntelliScore)","route":"/drugs/exodx-prostate/"},{"id":"myprostatescore-2","kind":"drug","name":"MyProstateScore 2.0","route":"/drugs/myprostatescore-2/"}],"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"technology":[{"id":"liquid-rna-biopsy","kind":"technology","name":"Liquid RNA biopsy (cell-free, vesicle and platelet RNA)","route":"/technologies/liquid-rna-biopsy/"},{"id":"prostate-screening-psa-mri","kind":"technology","name":"PSA and MRI-first prostate cancer screening","route":"/technologies/prostate-screening-psa-mri/"}],"company":[{"id":"mdxhealth","kind":"company","name":"MDxHealth","route":"/companies/mdxhealth/"}],"paper":[{"id":"paper-van-neste-urinary-biomarker-prostate-eur-urol-2016","kind":"paper","name":"Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score","route":"/key-papers/paper-van-neste-urinary-biomarker-prostate-eur-urol-2016/"}]}}